Poxel | Sustainability Performance
Poxel is a biopharmaceutical company focused on developing treatments for metabolic and neurodegenerative diseases. The company emphasizes innovative research and development to create effective therapies aimed at improving patient outcomes and addressing unmet needs.
2009
France
1,001 - 5,000 employees
Biotechnology
$1M - 10M in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#4910
Overall#324
in France#67
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Environmental
Digital emissionsGovernance
Targets
Digital Emissions
CO2e per visit (g)
Industry benchmark
B/M 0.26 g
B
Environmental ScoreScore B
Green HostingYes
Controversy level
- Poxel reported significant losses after clinical trial setbacks for its diabetes drug imeglimin in Western markets, raising going-concern risks.
Sustainability targets and commitments
| Target | Year | Value | Scope | Baseline |
|---|
